# Century Therapeutics share price today (Century Therapeutics, Inc., IPSC)

> Century Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. IPSC · Healthcare · Biotechnology · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/ipsc

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $1.52 (+162.1% in a year)
- Revenue (Mar 2025): $109 M (+12,667.7% on a year ago)
- Profit (Mar 2025): $76.6 M
- Operating margin: 67.7% (+3,729.6 points on a year ago)
- ROE: −6%, FY25
- ROIC: −25.2%, against a 12.4% cost of capital: −37.6 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Century Therapeutics share price today? Century Therapeutics, Inc.'s share price was $1.52 at the close on 3 November 2026. That is 27.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between $0 and $3, and at that close it sat 49% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 18 weeks running. Over the last 1 year the share price moved +153% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 2 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Century Therapeutics pay? Century Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Century Therapeutics on? Century Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Century Therapeutics profitable? Century Therapeutics, Inc. earned $76.6 M of net profit in the Mar 2025 quarter. The full FY25 year was a loss of $9.6 M. That is 70.1% of the quarter's revenue. The same quarter a year earlier lost $28.1 M. 11 of the last 12 reported quarters were loss-making. ## How much revenue does Century Therapeutics make, and is it growing? Century Therapeutics, Inc. reported $109 M of revenue in the Mar 2025 quarter, +12,667.7% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 3 years it has grown 175.9% a year on average. The last full year, FY25, came in at $109 M. The last four reported quarters add to $115 M. FY25 revenue was $109 M, +1,556.8% on the year before. Recent pace: the last four quarters grew +3,809.5% on average, against 175.9% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +8,286.8%, against +342.8% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Century Therapeutics keep? Century Therapeutics, Inc.'s operating margin was 67.7% in the Mar 2025 quarter, 3,729.6 percentage points higher than the same quarter a year ago. Across 4 years it has been between −5,600.9% and −13.8%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +3,729.6 percentage points on the year while gross margin changed +2,715.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Century Therapeutics' profit turning into cash? Century Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $104 M of cash, against −$9.6 M of profit. After $848 K of spending on assets, free cash was −$105 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Century Therapeutics' cash go? Century Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $14.7 M on assets over the last 3 years. Averaged over those years that is 4.5% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $14.7 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Century Therapeutics' P/E ratio, and how does it compare with its own history? Century Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Century Therapeutics, Inc. at 2.8× its FY25 revenue of $109 M. The P/E comes back here once profit turns positive. ## Is the Century Therapeutics business getting better or worse? Century Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Century Therapeutics earn on its capital? Century Therapeutics, Inc. earned a ROE of −6% in FY25. That is up from a low of −78% in FY24. Its return on capital used (ROIC) is 37.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −8.8% net margin and 0.49× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −8.8% net margin × 0.49× asset turnover × 1.41× leverage (assets divided by equity) ≈ −6.1% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −25.2% − 12.4% = −37.6 percentage points. The 12.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Century Therapeutics have too much debt? Century Therapeutics, Inc. has total debt of $38.7 M against shareholder equity of $232 M as of Jun 2026, so its debt is 0.17× its equity, which is very little. Year by year, that ratio went from 0.06 in FY21 to 0.27 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Century Therapeutics shareholding pattern? 28.8% of Century Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 37.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Century Therapeutics from balance-sheet trouble? For Century Therapeutics, Inc., the Z-score is −2.69. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −2.69 is inside the danger zone, so the balance sheet is a real risk. ## How does Century Therapeutics rank in its industry? There is no score against its industry: Century Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Century Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Century Therapeutics in size? Century Therapeutics is the 172nd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Enanta Pharmaceuticals, Inc., Arcturus Therapeutics Holdings Inc. and ARS Pharmaceuticals, Inc. Just below it: vTv Therapeutics Inc., Ocugen, Inc. and SAB Biotherapeutics, Inc. ### Biotechnology companies close in size

1. [Enanta Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/enta) $310 million
2. [Arcturus Therapeutics Holdings Inc.](https://www.sectoralpha.in/us/stocks/arct) $309 million
3. [ARS Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/spry) $303 million
4. Century Therapeutics, Inc. $302 million
5. [vTv Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/vtvt) $299 million
6. [Ocugen, Inc.](https://www.sectoralpha.in/us/stocks/ocgn) $297 million
7. [SAB Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/sabs) $289 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Alico, Inc.](https://www.sectoralpha.in/us/stocks/alco) $275 million · Farm Products
2. [Maui Land & Pineapple Company, Inc.](https://www.sectoralpha.in/us/stocks/mlp) $275 million · Real Estate Services
3. Century Therapeutics, Inc. $275 million
4. [USANA Health Sciences, Inc.](https://www.sectoralpha.in/us/stocks/usna) $275 million · Packaged Foods
5. [Blend Labs, Inc.](https://www.sectoralpha.in/us/stocks/blnd) $274 million · Software - Application

## What else do people ask about Century Therapeutics? ### What were Century Therapeutics's latest quarterly results? Century Therapeutics, Inc. reported revenue of $109 M and net profit of $76.6 M for the Mar 2025 quarter. Earnings per share were $0.89. The operating margin was 67.7%, 3,729.6 percentage points higher than a year earlier (as of 3 November 2026). ### What is Century Therapeutics's market cap? Century Therapeutics, Inc.'s market capitalisation is $302 M at a stock price of $1.52. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Century Therapeutics performing? Century Therapeutics, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 18 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Century Therapeutics's stock price go up? This page does not forecast Century Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $1.52. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Century Therapeutics in its business cycle? Century Therapeutics, Inc.'s FY25 operating margin was −13.8%, against a 4-year range of −5,600.9% to −13.8%: the middle of its own range, neither a peak nor a low. The latest quarter was 67.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Century Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Century Therapeutics a stock worth studying right now? What the numbers show: Century Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.